Rhenovia Pharma Language Contact
Search
   
       
    Rhenovia Pharma    
   

Investors & Market

Investors are welcome

Investors are welcome

At this very early stage, Rhenovia Pharma has based its financial strategy on four main sources of financial resources:

  • Personal team funding (capital, associates account, love money)
  • Revenues of the service activity
  • Public funding (national concourse of creation of innovative companies, OSEO, Region)
  • Private funding (business angels, investment funds).

Although the goal of Rhenovia's team is to self-finance its activities, various additional sources are essential to consolidate Rhenovia's platform portfolio and strengthen its competitive advantage.

Rhenovia private funding partners:

www.alsacebusinessangels.com/;  and www.sodiv.fr

A virtuous circle

A virtuous circle

Rhenovia has all the ingredients for an attractive investment:

  • it addresses urgent medical and societal needs
  • it targets a huge market in desperate search of new solutions
  • it already has developed technologies to address medical and pharmaceutical problems
  • it put in place a business model which facilitates rapid entry on the market
  • it has potentials for strong growth (with regard to the needs and the demands)
  • it has exciting development perspectives, as Rhenovia plans to capitalize on its own discoveries with the platforms to develop in the mid-term its own, proprietary pipeline of innovative therapeutics.

Epilepsie : Rhenovia dirigera RHENEPI, un projet labellisé de biosimulation d’un montant de 2,5 millions d’euros

Epilepsie : Rhenovia dirigera RHENEPI, un projet labellisé de biosimulation d’un montant de 2,5 millions d’euros
Epilepsie : Rhenovia dirigera RHENEPI, un projet labellisé de biosimulation d’un montant de 2,5 millions d’euros
avril 15th, 2010 par morgdave Leave a reply »
Rhenovia Pharma, une société biopharmaceutique spécialisée dans le développement de médicaments pour la maladie d’Alzheimer et d’autres maladies du système nerveux central et périphérique, va prendre la tête de RHENEPI, un projet de 2,5 millions d’euros. Objectif : développer et obtenir la validation expérimentale d’une plateforme de biosimulation de crises épileptiques afin d’identifier et tester de nouveaux médicaments et optimiser ceux déjà existants.